


Listing of the Claims

1. (Withdraw) A method of treating or preventing a disease or condition in which the inhibition of kinase Itk activity is beneficial comprising administering of a compound of formula (I)



(I)

wherein:

R^3 represents halogen, CN, C1 to 3 alkyl or C1 to 3 alkoxy;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

R^1 represents H, halogen, CN, C1 to 6 alkyl, NO_2 , SO_2Me , C1 to 6 alkynyl, CH_2OH , OR^2 , $(CH_2)_nNR^4R^5$ or phenyl optionally substituted by NH_2 ;

m represents an integer 1 or 2; and when m represents 2, each R^1 may be selected independently;

n represents an integer 0 or 1;

R^2 represents H or C1 to 4 alkyl; said C1 to 4 alkyl being optionally further substituted by a group selected from Ar^1 , $CONH_2$, CO_2Et , OH, NR^6R^7 , halogen and epoxy; and when substituted by NR^6R^7 or halogen, said alkyl is optionally further substituted by OH;

R^4 represents H, C1 to 4 alkyl or CH_2Ar^2 ;

R^5 represents H, C1 to 6 alkyl, C2 to 6 alkanoyl, SO_2-Ar^5 or CH_2Ar^2 ; said alkyl group being optionally further substituted by a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and NR^8 ;

or the group $-NR^4R^5$ together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and NR^8 ;

R^6 represents H, C1 to 4 alkyl or $CH_2CH_2OCH_3$;

R^7 represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl, Ar^3 , a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or CO_2Et ; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN, $CONMe_2$, $CONHMe$, C1 to 4 alkoxy, halogen, NMe_2 , Ar^4 , and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group $-NR^{6,7}$ together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and NR^9 ; and optionally substituted by one or more substituents selected independently from OH, NMe_2 , $CONH_2$, CH_2OH , CH_2CH_2OH , phenyl, pyridyl, piperidinyl or methoxyphenyl;

R^8 represents H, C1 to 6 alkyl or CH_2Ph ;

R^9 represents CH_2CH_2OH , $COCH_3$, Me, CO_2Et , CH_2CH_2OMe or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and CF_3 ;

R^{10} represents H, halogen, CN, C1 to 4 alkyl, C1 to 4 alkoxy, $NR^{14}R^{15}$ or a group $-X-Y-Z$;

R^{14} and R^{15} independently represent H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

X represents O, S, a bond or NR^{16} wherein R^{16} represents H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

Y represents C1 to 4 alkyl or a bond;

Z represents:

- i) phenyl, naphthyl or a 5- or 6-membered heteroaromatic ring system containing one to three heteroatoms independently selected from O, N and S; or
- ii) a five- or six-membered saturated heterocyclic ring containing one or two heteroatoms independently selected from O, N and S; said ring optionally being benzo fused; or

iii) C3 to 6 cycloalkyl;
said ring Z being optionally substituted by one or more substituents independently selected from halogen, OH, C1 to 4 alkyl, C1 to 4 alkoxy, hydroxymethyl, methylsulphonyl and $\text{NR}^{17}\text{R}^{18}$;

R^{17} and R^{18} independently represent H, C1 to 4 alkyl, formyl or C2 to alkanoyl; or the group $\text{NR}^{17}\text{R}^{18}$ together represents a saturated 5 to 7 membered azacyclic ring optionally containing one further heteroatom selected from O, N and S;

Ar^1 represents phenyl, thiazolyl or thiadiazolyl, optionally further substituted by halogen;

Ar^2 represents phenyl, a 5- or 6-membered heteroaromatic ring or a benzimidazole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or benzimidazole ring being optionally further substituted by one or two groups independently selected from halogen, C1 to 4 alkyl, CN, CH_2OH , C1 to 4 alkoxy, CO_2Me , CH_2OAc and pyridyl;

Ar^3 represents thiazolyl, triazolyl or tetrazolyl;

Ar^4 represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe;

Ar^5 represents phenyl, a 5- or 6-membered heteroaromatic ring or a quinoline ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or quinoline ring being optionally further substituted by halogen, C1 to 4 alkyl, CN, C1 to 4 alkoxy, and $\text{OCH}_2\text{CH}_2\text{CN}$;

or a pharmaceutically acceptable salt thereof.

2. (Withdrawn) The method according to Claim 1 wherein the disease or condition is Th2-driven and/or mast cell-driven and/or basophil driven disease or condition.

3. (Withdrawn) The method according to Claim 2 wherein the disease is asthma.

4. (Withdrawn) The method according to Claim 2 wherein the disease is allergic rhinitis.


5. (Withdrawn) The method according to Claims 1 wherein R^3 in formula (I) represents halogen.

6. (Withdrawn) The use according to Claims 1 wherein Ar in formula (I) represents phenyl.

7. (Withdrawn) The method according to Claims 1 wherein R^1 in formula (I) represents OR^2 or $(CH_2)_nNR^4R^5$.

8. (Withdrawn) The method according to any one of Claims 1 to 6 wherein R^{10} represents halogen, CN, C1 to 4 alkyl, C1 to 4 alkoxy, $NR^{14}R^{15}$ or a group $-X-Y-Z$.

9. (Withdrawn) A compound of formula (Ia)



(Ia)

wherein:

R^3 represents halogen, C1 to 3 alkyl or C1 to 3 alkoxy;

R^{10} represents H;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

m represents an integer 1 or 2;

when m represents 1, R^1 represents $(CH_2)_n R^4 R^5$ and n represents an integer 0 or 1;

when m represents 2, one R^1 represents chloro or OMe and the other R^1 represents $(CH_2)_n R^4 R^5$ and n represents an integer 0 or 1;

R^4 represents H or C1 to 4 alkyl;

R^5 represents $CH_2 Ar^2$;

Ar^2 represents phenyl, a 5- or 6-membered heteroaromatic ring or a benzimidazole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or benzimidazole ring being optionally further substituted by one or two groups independently selected from halogen, C1 to 4 alkyl, CN, CH_2OH , C1 to 4 alkoxy, CO_2Me , CH_2OAc and pyridyl;
or a pharmaceutically acceptable salt thereof.

10. (Withdrawn) A compound according to Claim 9 that is:

4-({[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino}methyl)benzonitrile

N-benzyl-*N*-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(1*H*-imidazol-2-ylmethyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(1*H*-imidazol-5-ylmethyl)amine

3-({[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino}methyl)benzonitrile

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(4-methoxybenzyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(2-methoxybenzyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(3-methoxybenzyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(2-chlorobenzyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(4-chlorobenzyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(1*H*-pyrazol-3-ylmethyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(3-chlorobenzyl)amine

[5-({[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino}methyl)-2-furyl]methanol

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(thien-2-ylmethyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(2-furylmethyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(thien-3-ylmethyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(4-methyl-1*H*-imidazol-5-yl)methyl]amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(3-furylmethyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(1,3-thiazol-2-ylmethyl)amine


N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(4-bromothiien-2-yl)methyl]amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(1*H*-imidazol-4-ylmethyl)amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(2-methyl-1*H*-imidazol-5-yl)methyl]amine

N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(3,5-dimethylisoxazol-4-yl)methyl]amine
 [5-({[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino} methyl)-2-furyl]methyl acetate
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(5-pyridin-2-ylthien-2-yl)methyl]amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(1-methyl-1*H*-benzimidazol-2-yl)methyl]amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(2-ethyl-1*H*-imidazol-5-yl)methyl]amine
N-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-[(1-methyl-1*H*-imidazol-5-yl)methyl]amine
 methyl 4-({[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino} methyl)-1-methyl-1*H*-pyrrole-2-carboxylate
N-benzyl-5-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)pyridin-2-amine
 5-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-*N*-(3-methoxybenzyl)pyridin-2-amine
 or a pharmaceutically acceptable salt thereof.

11. (Withdrawn) A compound of formula (Ib)



(Ib)

wherein:

R^3 represents halogen, C1 to 3 alkyl or C1 to 3 alkoxy;

R^{10} represents H;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

m represents an integer 1 or 2;

when m represents 1, R^1 represents OR^2 ;

when m represents 2, one R^1 represents chloro or OMe and the other R^1 represents OR^2 ;

R^2 represents C3 to 4 alkyl substituted by NR^6R^7 and by OH;

R^6 represents H, C1 to 4 alkyl or $CH_2CH_2OCH_3$;

R^7 represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl, Ar^3 , a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or CO_2Et ; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN, $CONMe_2$, $CONHMe$, C1 to 4 alkoxy, halogen, NMe_2 , Ar^4 , and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group $-NR^6R^7$ together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and NR^9 ; and optionally substituted by one or more substituents selected independently from OH, NMe_2 , $CONH_2$, CH_2OH , CH_2CH_2OH , phenyl, pyridyl, piperidinyl and methoxyphenyl;

R^9 represents CH_2CH_2OH , $COCH_3$, Me, CO_2Et , CH_2CH_2OMe or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and CF_3 ;

Ar^3 represents thiazolyl, triazolyl or tetrazolyl;

Ar^4 represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N

and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe;
or a pharmaceutically acceptable salt thereof.

12. (Withdrawn) A compound according to Claim 11 that is:

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-pyrrolidin-1-ylpropan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-morpholin-4-ylpropan-2-ol

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}pyrrolidin-3-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-piperidin-1-ylpropan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(diethylamino)propan-2-ol

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperidin-4-ol

1-(4-acetyl)piperazin-1-yl)-3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-{3-(dimethylamino)pyrrolidin-1-yl}propan-2-ol

4-[(2-hydroxy-3-[4-(6-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propyl)amino)methyl]phenol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-hydroxyethyl)(methyl)amino]propan-2-ol

3-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}(methyl)amino]propanenitrile

4-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}piperazin-1-ol

*N*²-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}-

*N*¹,*N*¹,*N*²-trimethylglycinamide

1-[benzyl(methyl)amino]-3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[methyl(2-phenylethyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(4-phenylpiperazin-1-yl)propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(4-pyridin-2-ylpiperazin-1-yl)propan-2-ol

1-[2-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} amino)ethyl]imidazolidin-2-one

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(3-methoxybenzyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-chlorobenzyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(4-chlorobenzyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(3-chlorobenzyl)amino]propan-2-ol

ethyl 4-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} amino)piperidine-1-carboxylate

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(cyclopropylamino)propan-2-ol

3-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} amino)propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-methoxyethyl)amino]propan-2-ol

2-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} amino)propan-1-ol

1-(benzylamino)-3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(pyridin-3-ylmethyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(pyridin-4-ylmethyl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(1-ethylpiperidin-3-yl)amino]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-morpholin-4-ylethyl)amino]propan-2-ol

1-[3-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl } amino)propyl]pyrrolidin-2-one

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} piperidin-3-ol

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} prolinamide

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(hydroxymethyl)piperidin-1-yl]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[2-(hydroxymethyl)piperidin-1-yl]propan-2-ol

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} piperidine-4-carboxamide

1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} piperidine-3-carboxamide

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(2-hydroxyethyl)piperazin-1-yl]propan-2-ol

2-(4-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} piperazin-1-yl)benzonitrile

6-(4-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl} piperazin-1-yl)nicotinonitrile


1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(1,3-thiazol-2-ylamino)propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(4-pyrazin-2-yl)piperazin-1-yl]propan-2-ol

1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[(2-methoxybenzyl)amino]propan-2-ol

4-[{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}(methylamino)cyclohexanecarbonitrile
 1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-(2-pyridin-3-ylpiperidin-1-yl)propan-2-ol
 1-{3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}-4-phenylpiperidin-4-ol
 2-({3-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-2-hydroxypropyl}amino)-3-methylbutan-1-ol
 1-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]-3-[4-(3-methoxyphenyl)piperazin-1-yl]propan-2-ol
 or a pharmaceutically acceptable salt thereof.

13. (Withdrawn) A compound of formula (Ic)



(Ic)

wherein:

R^3 represents halogen, C1 to 3 alkyl or C1 to 3 alkoxy;

R^{10} represents H;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

m represents an integer 1 or 2;

when m represents 1, R^1 represents OR^2 ;

when m represents 2, one R^1 represents chloro, NO_2 or OMe and the other R^1 represents OR^2 ;

R^2 represents C2 to 4 alkyl substituted by a group NR^6R^7 ;

R^6 represents H, C1 to 4 alkyl or $CH_2CH_2OCH_3$;

R^7 represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl, Ar^3 , a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or CO_2Et ; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN, $CONMe_2$, $CONHMe$, C1 to 4 alkoxy, halogen, NMe_2 , Ar^4 , and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group $-NR^6R^7$ together represents a 5 or 6 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and NR^9 ; and optionally substituted by one or more substituents selected independently from OH, NMe_2 , $CONH_2$, CH_2OH , CH_2CH_2OH , phenyl, pyridyl, piperidinyl or methoxyphenyl; R^9 represents CH_2CH_2OH , $COCH_3$, Me, CO_2Et , CH_2CH_2OMe or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and CF_3 ;

Ar^3 represents thiazolyl, triazolyl or tetrazolyl;

Ar^4 represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe;

or a pharmaceutically acceptable salt thereof,

with the provisos that:

- i) when R⁶ represents H or C1 to 4 alkyl, R³ does not represent unsubstituted C1 to 4 alkyl; and
- ii) that the group -NR⁶R⁷ does not represent unsubstituted morpholine, thiomorpholine, 4-methylpiperazine or 4-phenylpiperazine.

14. (Withdrawn) A compound according to Claim 13 that is:

6-bromo-2-[4-(2-{4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}ethoxy)phenyl]-3H-imidazo[4,5-*b*]pyridine
 6-bromo-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3H-imidazo[4,5-*b*]pyridine
 6-bromo-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-3H-imidazo[4,5-*b*]pyridine
 6-bromo-2-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-3H-imidazo[4,5-*b*]pyridine
N-(2-[4-(6-bromo-3H-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl)-*N*-(tetrahydrofuran-2-ylmethyl)amine
 6-bromo-2-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3H-imidazo[4,5-*b*]pyridine
 2-[{2-[4-(6-bromo-3H-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}(methyl)amino]ethanol
 3-[{2-[4-(6-bromo-3H-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}(methyl)amino]propanenitrile
 1-{2-[4-(6-bromo-3H-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}pyrrolidin-3-ol
 1-{2-[4-(6-bromo-3H-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}-*N,N*-dimethylpyrrolidin-3-amine
N-(2-[4-(6-bromo-3H-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl)-*N*,1-dimethylpyrrolidin-3-amine
N-2-~{2-[4-(6-bromo-3H-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}-
N~1~,*N*~1~,*N*~2~-trimethylglycinamide
N-(2-[4-(6-bromo-3H-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl)-*N*-ethyl-*N'*,*N'*-dimethylethane-1,2-diamine
N-benzyl-*N*-(2-[4-(6-bromo-3H-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl)-*N*-methylamine
 2-{4-[2-(4-acetyl)piperazin-1-yl]ethoxy}phenyl]-6-bromo-3H-imidazo[4,5-*b*]pyridine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N,N-bis(2-methoxyethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-methyl-N-(2-phenylethyl)amine

6-bromo-2-{4-[2-(4-pyridin-2-ylpiperazin-1-yl)ethoxy]phenyl}-3H-imidazo[4,5-b]pyridine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[3-(1H-imidazol-1-yl)propyl]amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(4-methoxybenzyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(3-methoxybenzyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(4-chlorobenzyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(3-chlorobenzyl)amine

ethyl 4-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)piperidine-1-carboxylate

6-bromo-2-(4-{2-[4-(2-methoxyethyl)piperazin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)propan-2-ol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-methoxyethyl)amine

2-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)propan-1-ol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-furylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(tetrahydrofuran-2-ylmethyl)amine

N-benzyl-N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(pyridin-3-ylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(pyridin-4-ylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(thien-2-ylmethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(1-phenylethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1-ethylpiperidin-3-amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-morpholin-4-ylethyl)amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-(2-methoxybenzyl)amine

1-[3-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl} amino)propyl]pyrrolidin-2-one

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[2-(4-chlorophenyl)ethyl]amine

4-[{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl} (methyl)amino]cyclohexanecarbonitrile

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl} piperidin-3-ol
6-bromo-2-{4-[2-(2-pyridin-3-ylpiperidin-1-yl)ethoxy]phenyl}-3H-imidazo[4,5-b]pyridine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-cyclopentylamine

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-4-phenylpiperidin-4-ol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[2-(1H-imidazol-4-yl)ethyl]amine

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl} piperidine-3-carboxamide

6-bromo-2-{4-[2-(4-pyrazin-2-ylpiperazin-1-yl)ethoxy]phenyl}-3H-imidazo[4,5-b]pyridine

(1*S*,2*S*)-2-({2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl} amino)cyclohexanol

6-bromo-2-(4-{2-[4-(3-methoxyphenyl)piperazin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidin-4-yl)methanol

4-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}amino)cyclohexanol

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidin-2-yl)methanol

1'-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1,4'-bipiperidine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1,3-thiazol-2-amine

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidine-4-carboxamide

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-1H-1,2,4-triazol-3-amine

2-(4-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperazin-1-yl)benzonitrile

6-(4-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperazin-1-yl)nicotinonitrile

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}prolinamide

6-bromo-2-(4-{2-[4-(2-methoxyphenyl)piperidin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine

2-(4-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperazin-1-yl)ethanol

1-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}piperidin-4-ol

6-bromo-2-(4-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethoxy}phenyl)-3H-imidazo[4,5-b]pyridine

(2*S*)-2-({2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl}amino)-3-methylbutan-1-ol

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-4,5-dihydro-1,3-thiazol-2-amine

N-{2-[4-(6-bromo-3H-imidazo[4,5-b]pyridin-2-yl)phenoxy]ethyl}-N-[2-(1H-indol-3-yl)ethyl]amine

(2*S*)-2-({2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl} amino)-2-phenylethanol

N- {2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl} -1*H*-tetrazol-5-amine


(1*S*,2*R*)-2-({2-[4-(6-bromo-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenoxy]ethyl} amino)cyclohexanol

6-chloro-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

6-bromo-2-[4-(2-morpholin-4-ylethoxy)-3-nitrophenyl]-3*H*-imidazo[4,5-*b*]pyridine

or a pharmaceutically acceptable salt thereof.

15. (Original) A compound of formula (Id)



(Id)

wherein:

R^3 represents halogen, CN, C1 to 3 alkyl or C1 to 3 alkoxy;

Ar represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S;

R^1 represents H, halogen, CN, C1 to 6 alkyl, NO_2 , SO_2Me , C1 to 6 alkynyl, CH_2OH ,

OR^2 , $(CH_2)_nNR^4R^5$ or phenyl optionally substituted by NH_2 ;

m represents an integer 1 or 2; and when m represents 2, each R^1 may be selected independently;

n represents an integer 0 or 1;

R^2 represents H or C1 to 4 alkyl; said C1 to 4 alkyl being optionally further substituted by a group selected from Ar^1 , $CONH_2$, CO_2Et , OH, NR^6R^7 , halogen and epoxy; and when substituted by NR^6R^7 or halogen, said alkyl is optionally further substituted by OH;

R^4 represents H, C1 to 4 alkyl or CH_2Ar^2 ;

R^5 represents H, C1 to 6 alkyl, C2 to 6 alkanoyl, SO_2-Ar^5 or CH_2Ar^2 ; said alkyl group being optionally further substituted by a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and NR^8 ; or the group $-NR^4R^5$ together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating one additional heteroatom selected from O, S and NR^8 ;

R^6 represents H, C1 to 4 alkyl or $CH_2CH_2OCH_3$;

R^7 represents H, C1 to 6 alkyl, C3 to 6 cycloalkyl, Ar^3 , a 5 or 6 membered saturated or partially unsaturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally substituted by Me, Et or CO_2Et ; said C1 to 6 alkyl being optionally substituted by one or more groups selected independently from OH, CN, $CONMe_2$, $CONHMe$, C1 to 4 alkoxy, halogen, NMe_2 , Ar^4 , and a 5 or 6 membered saturated heterocyclic ring incorporating 1 or 2 heteroatoms selected independently from O, N and S and optionally also incorporating a carbonyl group; said C3 to 6 cycloalkyl being optionally substituted by OH or CN;

or the group $-NR^6R^7$ together represents a 5 to 7 membered saturated azacyclic ring optionally incorporating 1 additional heteroatom selected from O and NR^9 ; and optionally substituted by one or more substituents selected independently from OH, NMe_2 , $CONH_2$, CH_2OH , CH_2CH_2OH , phenyl, pyridyl, piperidinyl or methoxyphenyl;

R^8 represents H, C1 to 6 alkyl or CH_2Ph ;

R^9 represents CH_2CH_2OH , $COCH_3$, Me, CO_2Et , CH_2CH_2OMe or a six membered aromatic or azaaromatic ring optionally further substituted by one or more substituents selected independently from Cl, CN, OMe and CF_3 ;

R^{10} represents halogen, CN, C1 to 4 alkyl, C1 to 4 alkoxy, $NR^{14}R^{15}$ or a group $-X-Y-Z$;

R^{14} and R^{15} independently represent H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

X represents O, S, a bond or NR^{16} wherein R^{16} represents H or C1 to 4 alkyl; said alkyl being optionally further substituted by OH;

Y represents C1 to 4 alkyl or a bond;

Z represents:

- i) phenyl, naphthyl or a 5- or 6-membered heteroaromatic ring system containing one to three heteroatoms independently selected from O, N and S; or
- ii) a five- or six-membered saturated heterocyclic ring containing one or two heteroatoms independently selected from O, N and S; said ring optionally being benzo fused; or
- iii) C3 to 6 cycloalkyl;

said ring Z being optionally substituted by one or more substituents independently selected from halogen, OH, C1 to 4 alkyl, C1 to 4 alkoxy, hydroxymethyl, methylsulphonyl and $NR^{17}R^{18}$;

R^{17} and R^{18} independently represent H, C1 to 4 alkyl, formyl or C2 to alkanoyl; or the group $NR^{17}R^{18}$ together represents a saturated 5 to 7 membered azacyclic ring optionally containing one further heteroatom selected from O, N and S;

Ar^1 represents phenyl, thiazolyl or thiadiazolyl, optionally further substituted by halogen;

Ar^2 represents phenyl, a 5- or 6-membered heteroaromatic ring or a benzimidazole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or benzimidazole ring being optionally further

substituted by one or two groups independently selected from halogen, C1 to 4 alkyl, CN, CH₂OH, C1 to 4 alkoxy, CO₂Me, CH₂OAc and pyridyl;

Ar³ represents thiazolyl, triazolyl or tetrazolyl;

Ar⁴ represents phenyl, a 5- or 6-membered heteroaromatic ring or an indole ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl, heteroaromatic or indole ring being optionally further substituted by one or two groups independently selected from halogen and OMe;

Ar⁵ represents phenyl, a 5- or 6-membered heteroaromatic ring or a quinoline ring; said heteroaromatic ring incorporating 1 to 3 heteroatoms independently selected from O, N and S; said phenyl or heteroaromatic or quinoline ring being optionally further substituted by halogen, C1 to 4 alkyl, CN, C1 to 4 alkoxy, and OCH₂CH₂CN;

with the proviso that when R¹⁰ represents halogen, C1 to 4 alkyl, C1 to 4 alkoxy or NH₂; and Ar represents phenyl; then said phenyl is not substituted at the 4-position by C1 to 2 alkoxy, OH, halogen or C1 to 4 alkyl.

16. (Original) A compound according to Claim 15 that is:

6,7-dichloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

6-chloro-*N*-(2-methoxyphenyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

2-[(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]phenol

6-chloro-*N*-[1-(methylsulfonyl)-3-pyrrolidinyl]-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-*N*-cyclopentyl-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

N-benzyl-6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-7-(1*H*-pyrrol-1-yl)-1*H*-imidazo[4,5-*b*]pyridine

1-(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)-3-pyrrolidinamine

1-(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)-3-pyrrolidinylformamide

6-chloro-*N*-(2-ethylphenyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-7-(2,3-dihydro-1*H*-indol-1-yl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-7-(4-morpholinyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-*N*-pyridin-3-yl-3*H*-imidazo[4,5-*b*]pyridin-7-amine

[3-({6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridin-7-yl}amino)phenyl]methanol

6-chloro-*N*-(2-fluorophenyl)-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-*N*-phenyl-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-*N*-(3-ethylphenyl)-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

2-[benzyl(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]ethanol

2-[(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]ethanol

N-benzyl-6-chloro-*N*-methyl-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-*N*-methyl-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

7-(benzylthio)-6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-*N*-[4-(methylsulfonyl)phenyl]-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-*N*-[4-(4-morpholinyl)phenyl]-1*H*-imidazo[4,5-*b*]pyridin-7-amine

N-(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)-*N,N*-diethyl-1,4-benzenediamine

N-{4-[(6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-1*H*-imidazo[4,5-*b*]pyridin-7-yl)amino]phenyl}acetamide

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-7-phenoxy-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-{4-[2-(4-morpholinyl)ethoxy]phenyl}-7-[2-(1-pyrrolidinyl)ethoxy]-1*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-*N*-(2-morpholin-4-ylethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-7-pyrrolidin-1-yl-3*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-*N*-(1-phenylethyl)-3*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-7-(4-methylphenyl)-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

6-chloro-7-(3-methoxyphenyl)-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

N-(3-{6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridin-7-yl}phenyl)acetamide

6-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-7-thien-3-yl-3*H*-imidazo[4,5-*b*]pyridine

2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine-6,7-dicarbonitrile

7-chloro-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine-6-carbonitrile

7-anilino-2-(4-{2-[(2-methoxyethyl)(methyl)amino]ethoxy}phenyl)-3*H*-imidazo[4,5-*b*]pyridine-6-carbonitrile

6,7-dichloro-2-[4-[2-(4-morpholinyl)ethoxy]-3-nitrophenyl]-1*H*-imidazo[4,5-*b*]pyridine
 5-(6,7-dichloro-1*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-[2-(4-morpholinyl)ethoxy]aniline
 2-amino-5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenol
 5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-([(2*R*)-pyrrolidin-2-ylmethyl]amino} phenol
 [5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-(2-morpholin-4-ylethoxy)phenyl][(2*R*)-pyrrolidin-2-ylmethyl]amine
 4-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-*N*¹-(2-morpholin-4-ylethyl)benzene-1,2-diamine
 [5-(6-chloro-7-methyl-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-(4-methylpiperazin-1-yl)phenyl]amine
 6,7-dichloro-2-[4-(4-morpholinyl)phenyl]-1*H*-imidazo[4,5-*b*]pyridine
 [5-(6,7-dichloro-3*H*-imidazo[4,5-*b*]pyridin-2-yl)-2-morpholin-4-ylphenyl]amine
 2-(4-aminophenyl)-6-chloro-*N*-phenyl-3*H*-imidazo[4,5-*b*]pyridin-7-amine
N-[4-(6,7-dichloro-3*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-*N*-(2-morpholin-4-ylethyl)amine
 6-bromo-7-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine
 6-bromo-7-methyl-2-(4-nitrophenyl)-1*H*-imidazo[4,5-*b*]pyridine
 4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)aniline
N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-3-cyanobenzenesulfonamide
N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-cyanobenzenesulfonamide
N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]quinoline-8-sulfonamide
N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-methoxybenzenesulfonamide
N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-(2-cyanoethoxy)benzenesulfonamide
N-[4-(6-bromo-7-methyl-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-1-methyl-1*H*-imidazole-4-sulfonamide

N-[4-(6,7-dichloro-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-

methoxybenzenesulfonamide

6-chloro-2-{4-[(2-morpholin-4-ylethyl)amino]phenyl}-*N*-phenyl-3*H*-imidazo[4,5-*b*]pyridin-7-amine

6-chloro-7-methoxy-2-[4-(2-morpholin-4-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

6-chloro-2-{4-[di(3-cyanobenzyl)amino]phenyl}-7-methoxy-1-yl-3*H*-imidazo[4,5-*b*]pyridine

3-({[4-(6-chloro-7-methoxy-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]amino}methyl)benzonitrile)

N-[4-(6-chloro-7-methoxy-1*H*-imidazo[4,5-*b*]pyridin-2-yl)phenyl]-4-cyanobenzenesulfonamide


6-chloro-7-methoxy-2-[4-(2-piperidin-1-ylethoxy)phenyl]-3*H*-imidazo[4,5-*b*]pyridine

or a pharmaceutically acceptable salts thereof.

17. (Cancelled)

18. (Withdrawn) A process for the preparation of a compound of formula (Ia) according to Claim 9 which comprises:


a) reaction of a compound of the general formula (II):



(II)

in which R³ and R¹⁰ are as defined in Claim 9


with a compound of formula (III):



(III)

in which m , R^1 and Ar are as defined in Claim 9, in the presence of an oxidizing agent; or


b) reaction of a compound of the general formula (II):



(II)

in which R^3 and R^{10} are as defined in Claim 9,


with a compound of formula (IV):



(IV)

in which m , R^1 and Ar are as defined in Claim 9, in the presence of POCl_3 ; or

d) reaction of a compound of the general formula (VII):



(VII)

in which n , R^3 , R^{10} and Ar are as defined in Claim 9;

with a compound of formula (VIII):



in which Ar^2 is as defined in Claim 9

and where desired or necessary converting the resultant compound of formula (Ia) or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Ia) into another compound of formula (Ia); and where desired converting the resultant compound of formula (Ia) into an optical isomer thereof.

19. (Withdrawn) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Ia) according to Claim 9, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.


20. (Withdrawn) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Ib) according to Claim 11, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

21. (Withdrawn) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Ic) according to Claim 13, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

22. (Original) A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (Id) according to Claim 15, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.


23. (Withdrawn) A process for the preparation of a compound of formula (Ib) according to Claims 11 which comprises:

a) reaction of a compound of the general formula (II):



(II)


in which R^3 and R^{10} are as defined in Claim 11,
with a compound of formula (III):



(III)


in which R^1 and Ar are as defined in Claim 11, in the presence of an oxidizing agent;
or

b) reaction of a compound of the general formula (II):



(II)


in which R^3 and R^{10} are as defined in Claim 11,
with a compound of formula (IV):



(IV)

in which m , R^1 and Ar are as defined in Claim 11, in the presence of $POCl_3$; or

c) reaction of a compound of formula (V):



(V)


in which R^3 , R^{10} and Ar are as defined in Claim 11;

with a compound of formula (VI):



in which R^2 is as defined in Claim 11 and LG represents a leaving group; or

c) reaction of a compound of the general formula (IX):



(IX)

in which R^3 , R^{10} and Ar are as defined in Claim 11;

with a compound of formula (X):




in which R^6 and R^7 are as defined in Claim 11;

and where desired or necessary converting the resultant compound of formula (Ib) or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Ib) into another compound of formula (Ib); and where desired converting the resultant compound of formula (Ib) into an optical isomer thereof.


24. (Withdrawn) A process for the preparation of a compound of formula (Ic) according to any one of Claims 13 which comprises:

- a) reaction of a compound of the general formula (II):



(II)


in which R^3 and R^{10} are as defined in Claim 13,
with a compound of formula (III):



(III)

in which m , R^1 and Ar are as defined in Claim 13 in the presence of an oxidizing agent;
or


- b) reaction of a compound of the general formula (II):



(II)

in which R^3 and R^{10} are as defined in Claim 13,


with a compound of formula (IV):



(IV)

in which m , R^1 and Ar are as defined in Claim 13, in the presence of POCl_3 ; or

c) reaction of a compound of formula (V):



(V)

in which R^3 , R^{10} and Ar are as defined in Claim 13;

with a compound of formula (VI):




in which R^2 is as defined in Claim 13 and LG represents a leaving group; or

and where desired or necessary converting the resultant compound of formula (Ic) or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Ic) into another compound of formula (Ic); and where desired converting the resultant compound of formula (Ic) into an optical isomer thereof.


25. (Currently Amended) A process for the preparation of a compound of formula (Id) according to Claim 15 which comprises:

- a) reaction of a compound of the general formula (II):



(II)


in which R^3 and R^{10} are as defined in Claim 15,
with a compound of formula (III):



(III)

in which m , R^1 and Ar are as defined in Claim 15,
in the presence of an oxidizing agent to give a compound of formula (Id); or


- b) reaction of a compound of the general formula (II):



(II)

in which R^3 and R^{10} are as defined in Claim 15,

with a compound of formula (IV):




(IV)

in which m , R^1 and Ar are as defined in Claim 15,

in the presence of $POCl_3$ to give a compound of formula (Id); or

c) reaction of a compound of formula (V):



(V)


in which R^3 , R^{10} and Ar are as defined in claim 15;

with a compound of formula (VI):



in which R^2 is as defined in Claim 15 and LG represents a leaving group,
to give a compound of formula (1d) wherein m is 1 and R^1 is OR^2 in which R^2 is as defined in Claim 15; or

d) reaction of a compound of the general formula (VII):




(VII)

in which n, R^3 , R^{10} and Ar are as defined in Claim 15;
 with a compound of formula (VIII):



in which Ar^2 is as defined in Claim 15,
to give a compound of formula (1d) wherein m is 1 and R^1 is $(CH_2)_nNR^4R^5$ in which R^4 is CH_2Ar^2 and R^5 is H or CH_2Ar^2 and Ar^2 is as defined in Claim 15; or

e) reaction of a compound of the general formula (IX):



(IX)

in which R^3 , R^{10} and Ar are as defined in Claim 15;

with a compound of formula (X):



in which R^6 and R^7 are as defined in Claim 15,

to give a compound of formula (1d) wherein m is 1 and R^1 is OR^2 in which R^2 is C_3 -alkyl being substituted by OH and NR^6R^7 and where R^6 and R^7 are as defined in Claim 15;

and where desired or necessary converting the resultant compound of formula (Id) or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Id) into another compound of formula (Id); and where desired converting the resultant compound of formula (Id) into an optical isomer thereof.